Trials / Completed
CompletedNCT04292899
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4,891 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remdesivir | Administered as an intravenous infusion |
| DRUG | Standard of Care | Standard of Care Treatment for COVID-19 Infection |
Timeline
- Start date
- 2020-03-06
- Primary completion
- 2020-04-09
- Completion
- 2020-06-30
- First posted
- 2020-03-03
- Last updated
- 2020-12-31
- Results posted
- 2020-12-31
Locations
183 sites across 15 countries: United States, China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04292899. Inclusion in this directory is not an endorsement.